Afatinib plus PEM and CBDCA overcome osimertinib resistance in <i>EGFR</i>‐mutated NSCLC with high thrombospondin‐1 expression
Naomi Onda(Nippon Medical School), Masahiro Seike(Nippon Medical School Hospital)
Cited by 7
Related Papers
AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier
|Oncology Reports|2017|19
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
|JTO Clinical and Research Reports|2024|7